Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Malignant Lymphoma

  Free Subscription

Articles published in Leukemia

Retrieve available abstracts of 80 articles:
HTML format

Single Articles

    May 2023
  1. BERNING P, Schmitz N, Ngoya M, Finel H, et al
    Allogeneic hematopoietic stem cell transplantation for NK/T-cell lymphoma: an international collaborative analysis.
    Leukemia. 2023 May 8:1-10. doi: 10.1038/s41375-023-01924.
    PubMed     Abstract available

  2. PASTORET C, Llamas-Gutierrez F, Fouchard M, Moignet A, et al
    Molecular mechanisms underlying transformation of large granular lymphocytic leukemia to high-grade T-cell lymphoma.
    Leukemia. 2023 May 4. doi: 10.1038/s41375-023-01922.

  3. SHOMALI W, Colucci P, George TI, Kiladjian JJ, et al
    Comprehensive response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: a proposal from the MLN International Working Group.
    Leukemia. 2023;37:981-987.

    April 2023
  4. XIA Y, Sun T, Li G, Li M, et al
    Spatial single cell analysis of tumor microenvironment remodeling pattern in primary central nervous system lymphoma.
    Leukemia. 2023 Apr 29. doi: 10.1038/s41375-023-01908.
    PubMed     Abstract available

  5. ANAGNOSTOU T, Yang ZZ, Jalali S, Kim HJ, et al
    Characterization of immune exhaustion and suppression in the tumor microenvironment of splenic marginal zone lymphoma.
    Leukemia. 2023 Apr 28. doi: 10.1038/s41375-023-01911.
    PubMed     Abstract available

  6. ARAUJO-AYALA F, Dobano-Lopez C, Valero JG, Nadeu F, et al
    A novel patient-derived 3D model recapitulates mantle cell lymphoma lymph node signaling, immune profile and in vivo ibrutinib responses.
    Leukemia. 2023 Apr 8. doi: 10.1038/s41375-023-01885.
    PubMed     Abstract available

  7. HEMMINKI K, Hemminki J, Forsti A, Sud A, et al
    Survival in hematological malignancies in the Nordic countries through a half century with correlation to treatment.
    Leukemia. 2023;37:854-863.
    PubMed     Abstract available

  8. KROONEN JS, de Graaf IJ, Kumar S, Remst DFG, et al
    Inhibition of SUMOylation enhances DNA hypomethylating drug efficacy to reduce outgrowth of hematopoietic malignancies.
    Leukemia. 2023;37:864-876.
    PubMed     Abstract available

    March 2023
  9. MANOS K, Chong G, Keane C, Lee ST, et al
    Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP study.
    Leukemia. 2023 Mar 11. doi: 10.1038/s41375-023-01863.
    PubMed     Abstract available

    February 2023
  10. GOSSAI N, Bhojwani D, Schafer ES, Chang BH, et al
    Patients with Down syndrome can be included in early phase clinical trials- a report from the T2016-003 Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) study.
    Leukemia. 2023 Feb 22. doi: 10.1038/s41375-023-01856.

  11. YUAN R, Wang MY, Bi C, Zhao X, et al
    MCL1 as a therapeutic vulnerability in Burkitt lymphoma.
    Leukemia. 2023 Feb 2. doi: 10.1038/s41375-023-01827.

  12. LIM SK, Peng CC, Low S, Vijay V, et al
    Sustained activation of non-canonical NF-kappaB signalling drives glycolytic reprogramming in doxorubicin-resistant DLBCL.
    Leukemia. 2023;37:441-452.
    PubMed     Abstract available

    January 2023
  13. CHIAPPELLA A, Dodero A, Evangelista A, Re A, et al
    Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma: results of the PTCL13 phase Ib/II study.
    Leukemia. 2023 Jan 18. doi: 10.1038/s41375-022-01780.
    PubMed     Abstract available

  14. FRONTZEK F, Staiger AM, Wullenkord R, Grau M, et al
    Molecular profiling of EBV associated diffuse large B-cell lymphoma.
    Leukemia. 2023 Jan 5. doi: 10.1038/s41375-022-01804.
    PubMed     Abstract available

  15. JIMENEZ-UBIETO A, Poza M, Martin-Munoz A, Ruiz-Heredia Y, et al
    Real-life disease monitoring in follicular lymphoma patients using liquid biopsy ultra-deep sequencing and PET/CT.
    Leukemia. 2023 Jan 3. doi: 10.1038/s41375-022-01803.
    PubMed     Abstract available

  16. FALINI B, Martino G, Lazzi S
    A comparison of the International Consensus and 5th World Health Organization classifications of mature B-cell lymphomas.
    Leukemia. 2023;37:18-34.
    PubMed     Abstract available

    December 2022
  17. CASEY M, Segawa K, Law SC, Sabdia MB, et al
    Inhibition of CD39 unleashes macrophage antibody-dependent cellular phagocytosis against B-cell lymphoma.
    Leukemia. 2022 Dec 20. doi: 10.1038/s41375-022-01794.
    PubMed     Abstract available

  18. SHINGAKI S, Koya J, Yuasa M, Saito Y, et al
    Tumor-promoting function and regulatory landscape of PD-L2 in B-cell lymphoma.
    Leukemia. 2022 Dec 15. doi: 10.1038/s41375-022-01772.

  19. LI S, Qiu L, Xu J, Lin P, et al
    High-grade B-cell lymphoma (HGBL)-NOS is clinicopathologically and genetically more similar to DLBCL/HGBL-DH than DLBCL.
    Leukemia. 2022 Dec 13. doi: 10.1038/s41375-022-01778.
    PubMed     Abstract available

  20. SUREDA-GOMEZ M, Balsas P, Rodriguez ML, Nadeu F, et al
    Tumorigenic role of Musashi-2 in aggressive mantle cell lymphoma.
    Leukemia. 2022 Dec 12. doi: 10.1038/s41375-022-01776.
    PubMed     Abstract available

  21. WEI W, Song Z, Chiba M, Wu W, et al
    Analysis and therapeutic targeting of the EP300 and CREBBP acetyltransferases in anaplastic large cell lymphoma and Hodgkin lymphoma.
    Leukemia. 2022 Dec 1. doi: 10.1038/s41375-022-01774.
    PubMed     Abstract available

  22. HUSBY S, Baech-Laursen C, Eskelund CW, Favero F, et al
    Clonal hematopoiesis is associated with hematological toxicity during lenalidomide-based therapy for MCL.
    Leukemia. 2022;36:2912-2916.

    November 2022
  23. AU-YEUNG RKH, Padilla LA, Zimmermann M, Reinke S, et al
    Frequency and prognostic implications of KMT2A rearrangements in children with precursor B-cell lymphoma.
    Leukemia. 2022 Nov 9. pii: 10.1038/s41375-022-01757.

  24. LI XY, Wu JC, Liu P, Li ZJ, et al
    Inhibition of USP1 reverses the chemotherapy resistance through destabilization of MAX in the relapsed/refractory B-cell lymphoma.
    Leukemia. 2022 Nov 9. pii: 10.1038/s41375-022-01747.
    PubMed     Abstract available

  25. XU W, Berning P, Erdmann T, Grau M, et al
    mTOR inhibition amplifies the anti-lymphoma effect of PI3Kbeta/delta blockage in diffuse large B-cell lymphoma.
    Leukemia. 2022 Nov 9. pii: 10.1038/s41375-022-01749.
    PubMed     Abstract available

  26. ALARCON TOMAS A, Fein JA, Fried S, Flynn JR, et al
    Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma.
    Leukemia. 2022 Nov 5. pii: 10.1038/s41375-022-01739.
    PubMed     Abstract available

  27. STRATI P, Jallouk AP, Sun R, Choi J, et al
    Impact of conditioning chemotherapy on lymphocyte kinetics and outcomes in LBCL patients treated with CAR T-cell therapy.
    Leukemia. 2022;36:2669-2677.
    PubMed     Abstract available

    October 2022
  28. BERNDT SI, Vijai J, Benavente Y, Camp NJ, et al
    Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes.
    Leukemia. 2022 Oct 22. pii: 10.1038/s41375-022-01711.
    PubMed     Abstract available

  29. SEIFERT R, Kersting D, Rischpler C, Sandach P, et al
    Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification: a post-hoc analysis of the PETAL trial.
    Leukemia. 2022 Oct 14. pii: 10.1038/s41375-022-01713.
    PubMed     Abstract available

  30. DRIESSEN J, Kersten MJ, Visser L, van den Berg A, et al
    Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP.
    Leukemia. 2022 Oct 14. pii: 10.1038/s41375-022-01717.
    PubMed     Abstract available

    September 2022
  31. COX MC, Marcheselli L, Scafetta G, Visco C, et al
    IgM-secreting diffuse large B-cell lymphoma: results of a multicentre clinicopathological and molecular study.
    Leukemia. 2022 Sep 20. pii: 10.1038/s41375-022-01706.

  32. THOMPSON PA, Jiang X, Banerjee P, Basar R, et al
    A phase two study of high dose blinatumomab in Richter's syndrome.
    Leukemia. 2022;36:2228-2232.
    PubMed     Abstract available

    August 2022
  33. WANG H, Fu BB, Wuxiao ZJ, Li YJ, et al
    A prognostic survival nomogram for persons with extra-nodal natural killer-/T-cell lymphoma.
    Leukemia. 2022 Aug 15. pii: 10.1038/s41375-022-01679.

  34. FREEMAN CL, Pararajalingam P, Jin L, Balasubramanian S, et al
    Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial.
    Leukemia. 2022 Aug 13. pii: 10.1038/s41375-022-01658.
    PubMed     Abstract available

  35. MENDEVILLE M, Janssen J, Kim Y, van Dijk E, et al
    A bioinformatics perspective on molecular classification of diffuse large B-cell lymphoma.
    Leukemia. 2022 Aug 6. pii: 10.1038/s41375-022-01670.

  36. MONTES-MOJARRO IA, Steinhilber J, Griessinger CM, Rau A, et al
    CD147 a direct target of miR-146a supports energy metabolism and promotes tumor growth in ALK+ ALCL.
    Leukemia. 2022;36:2050-2063.
    PubMed     Abstract available

    July 2022
  37. MENTZ M, Keay W, Strobl CD, Antoniolli M, et al
    PARP14 is a novel target in STAT6 mutant follicular lymphoma.
    Leukemia. 2022 Jul 18. pii: 10.1038/s41375-022-01641.
    PubMed     Abstract available

  38. BAZARBACHI A, Boumendil A, Finel H, Khvedelidze I, et al
    Correction: The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years.
    Leukemia. 2022 Jul 15. pii: 10.1038/s41375-022-01639.

  39. HONG Y, Ren T, Wang X, Liu X, et al
    APR-246 triggers ferritinophagy and ferroptosis of diffuse large B-cell lymphoma cells with distinct TP53 mutations.
    Leukemia. 2022 Jul 14. pii: 10.1038/s41375-022-01634.
    PubMed     Abstract available

  40. MOKER P, Zur Stadt U, Zimmermann M, Alawi M, et al
    Characterization of IG-MYC-breakpoints and their application for quantitative minimal disease monitoring in high-risk pediatric Burkitt-lymphoma and -leukemia.
    Leukemia. 2022 Jul 5. pii: 10.1038/s41375-022-01626.

  41. ALAGGIO R, Amador C, Anagnostopoulos I, Attygalle AD, et al
    The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.
    Leukemia. 2022;36:1720-1748.
    PubMed     Abstract available

  42. CHEN L, Zheng Y, Yu K, Chen S, et al
    Changing causes of death in persons with haematological cancers 1975-2016.
    Leukemia. 2022;36:1850-1860.
    PubMed     Abstract available

    June 2022
  43. THUS YJ, Eldering E, Kater AP, Spaargaren M, et al
    Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma.
    Leukemia. 2022 Jun 20. pii: 10.1038/s41375-022-01627.
    PubMed     Abstract available

  44. LAUER EM, Mutter J, Scherer F
    Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research.
    Leukemia. 2022 Jun 14. pii: 10.1038/s41375-022-01618.
    PubMed     Abstract available

  45. DONG G, Liu X, Wang L, Yin W, et al
    Genomic profiling identifies distinct genetic subtypes in extra-nodal natural killer/T-cell lymphoma.
    Leukemia. 2022 Jun 13. pii: 10.1038/s41375-022-01623.
    PubMed     Abstract available

    May 2022
  46. FERRERI AJM, Cwynarski K, Pulczynski E, Fox CP, et al
    Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial.
    Leukemia. 2022 May 13. pii: 10.1038/s41375-022-01582.
    PubMed     Abstract available

  47. KAMEDA K, Kako S, Kim SW, Usui Y, et al
    Autologous or allogeneic hematopoietic cell transplantation for relapsed or refractory PTCL-NOS or AITL.
    Leukemia. 2022;36:1361-1370.
    PubMed     Abstract available

    April 2022
  48. ZHOU W, Xu Y, Zhang J, Zhang P, et al
    MiRNA-363-3p/DUSP10/JNK axis mediates chemoresistance by enhancing DNA damage repair in diffuse large B-cell lymphoma.
    Leukemia. 2022 Apr 29. pii: 10.1038/s41375-022-01565.
    PubMed     Abstract available

  49. WONG J, Gruber E, Maher B, Waltham M, et al
    Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma.
    Leukemia. 2022 Apr 22. pii: 10.1038/s41375-022-01571.
    PubMed     Abstract available

  50. BAZARBACHI A, Boumendil A, Finel H, Khvedelidze I, et al
    The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years.
    Leukemia. 2022 Apr 12. pii: 10.1038/s41375-022-01563.
    PubMed     Abstract available

    March 2022
  51. DINNESSEN MAW, Maas CCHM, Tonino SH, Visser O, et al
    Causes of death of patients with follicular lymphoma in the Netherlands by stage and age groups: a population-based study in the pre- and post-rituximab era.
    Leukemia. 2022 Mar 4. pii: 10.1038/s41375-022-01535.

    February 2022
  52. DAHL M, Husby S, Eskelund CW, Besenbacher S, et al
    Correction: Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma: a study of younger patients from the MCL2 and MCL3 clinical trials.
    Leukemia. 2022 Feb 18. pii: 10.1038/s41375-022-01526.

  53. MARCHESI F, Pimpinelli F, Giannarelli D, Ronchetti L, et al
    Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin's lymphomas.
    Leukemia. 2022;36:588-590.

    January 2022
  54. LIM TL, Lieberman DB, Davis AR, Loren AW, et al
    Germline POT1 variants can predispose to myeloid and lymphoid neoplasms.
    Leukemia. 2022;36:283-287.

    November 2021
  55. BERTRAM K, Leary PJ, Boudesco C, Fullin J, et al
    Inhibitors of Bcl-2 and Bruton's tyrosine kinase synergize to abrogate diffuse large B-cell lymphoma growth in vitro and in orthotopic xenotransplantation models.
    Leukemia. 2021 Nov 18. pii: 10.1038/s41375-021-01470.
    PubMed     Abstract available

  56. REUTTER K, Sandmann S, Rohde J, Muller S, et al
    Publisher Correction: Reconstructing clonal evolution in relapsed and non-relapsed Burkitt lymphoma.
    Leukemia. 2021 Nov 16. pii: 10.1038/s41375-021-01359.

  57. SPANJAART AM, Ljungman P, de La Camara R, Tridello G, et al
    Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European He
    Leukemia. 2021 Nov 8. pii: 10.1038/s41375-021-01466.

    October 2021
  58. NEWMAN AM, Zaka M, Zhou P, Blain AE, et al
    Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma.
    Leukemia. 2021 Oct 21. pii: 10.1038/s41375-021-01444.
    PubMed     Abstract available

  59. BROCKELMANN PJ, Muller H, Gillessen S, Yang X, et al
    Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis.
    Leukemia. 2021 Oct 9. pii: 10.1038/s41375-021-01442.
    PubMed     Abstract available

    September 2021
  60. GARCIA-MARQUEZ MA, Thelen M, Reinke S, Keller D, et al
    Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma.
    Leukemia. 2021 Sep 28. pii: 10.1038/s41375-021-01421.
    PubMed     Abstract available

  61. TAMAKI K, Morishima S, Suzuki S, Shigenari A, et al
    Full-length HLA sequencing in adult T cell leukemia-lymphoma uncovers multiple gene alterations.
    Leukemia. 2021 Sep 13. pii: 10.1038/s41375-021-01403.

  62. WANG H, Fu BB, Gale RP, Liang Y, et al
    NK-/T-cell lymphomas.
    Leukemia. 2021;35:2460-2468.
    PubMed     Abstract available

    August 2021
  63. VILARRASA-BLASI R, Verdaguer-Dot N, Belver L, Soler-Vila P, et al
    Insights into the mechanisms underlying aberrant SOX11 oncogene expression in mantle cell lymphoma.
    Leukemia. 2021 Aug 28. pii: 10.1038/s41375-021-01389.

  64. DAMASCHIN C, Goergen H, Kreissl S, Plutschow A, et al
    Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group.
    Leukemia. 2021 Aug 18. pii: 10.1038/s41375-021-01386.

  65. YANG Y, Wang Y, Liu X, He X, et al
    Correction to: Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study.
    Leukemia. 2021 Aug 2. pii: 10.1038/s41375-021-01371.

    July 2021
  66. ROSSI A, Orecchioni S, Falvo P, Tabanelli V, et al
    Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma.
    Leukemia. 2021 Jul 24. pii: 10.1038/s41375-021-01347.
    PubMed     Abstract available

  67. LOWENBERG B, Kersten MJ, Gale RP, van Oers M, et al
    Prof. Anton Hagenbeek 1948-2021: Father of MRD and Lymphoma Expert.
    Leukemia. 2021 Jul 20. pii: 10.1038/s41375-021-01310.

  68. ZHANG Y, Wang Y, Liu Y, Tong C, et al
    Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1-2 trial.
    Leukemia. 2021 Jul 16. pii: 10.1038/s41375-021-01345.
    PubMed     Abstract available

  69. DAHL M, Husby S, Eskelund CW, Besenbacher S, et al
    Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma: a study of younger patients from the MCL2 and MCL3 clinical trials.
    Leukemia. 2021 Jul 9. pii: 10.1038/s41375-021-01311.
    PubMed     Abstract available

  70. PRITCHETT JC, Yang ZZ, Kim HJ, Villasboas JC, et al
    High-dimensional and single-cell transcriptome analysis of the tumor microenvironment in angioimmunoblastic T cell lymphoma (AITL).
    Leukemia. 2021 Jul 6. pii: 10.1038/s41375-021-01321.
    PubMed     Abstract available

  71. HUBSCHMANN D, Kleinheinz K, Wagener R, Bernhart SH, et al
    Mutational mechanisms shaping the coding and noncoding genome of germinal center derived B-cell lymphomas.
    Leukemia. 2021;35:2002-2016.
    PubMed     Abstract available

  72. SASI B, Ethiraj P, Myers J, Lin AP, et al
    Regulation of PD-L1 expression is a novel facet of cyclic-AMP-mediated immunosuppression.
    Leukemia. 2021;35:1990-2001.
    PubMed     Abstract available

    June 2021
  73. GRAHAM CE, Jozwik A, Quartey-Papafio R, Ioannou N, et al
    Gene-edited healthy donor CAR T cells show superior anti-tumour activity compared to CAR T cells derived from patients with lymphoma in an in vivo model of high-grade lymphoma.
    Leukemia. 2021 Jun 18. pii: 10.1038/s41375-021-01324.

  74. JACHIMOWICZ RD, Klapper W, Glehr G, Muller H, et al
    Gene expression-based outcome prediction in advanced stage classical Hodgkin lymphoma treated with BEACOPP.
    Leukemia. 2021 Jun 10. pii: 10.1038/s41375-021-01314.

  75. POGLIO S, Prochazkova-Carlotti M, Cherrier F, Gros A, et al
    Xenograft and cell culture models of Sezary syndrome reveal cell of origin diversity and subclonal heterogeneity.
    Leukemia. 2021;35:1696-1709.
    PubMed     Abstract available

    May 2021
  76. LITTLE MP, Wakeford R, Zablotska LB, Borrego D, et al
    Lymphoma and multiple myeloma in cohorts of persons exposed to ionising radiation at a young age.
    Leukemia. 2021 May 28. pii: 10.1038/s41375-021-01284.
    PubMed     Abstract available

  77. WU F, Watanabe N, Tzioni MM, Akarca A, et al
    Thyroid MALT lymphoma: self-harm to gain potential T-cell help.
    Leukemia. 2021 May 21. pii: 10.1038/s41375-021-01289.
    PubMed     Abstract available

  78. HE MY, Kridel R
    Treatment resistance in diffuse large B-cell lymphoma.
    Leukemia. 2021 May 20. pii: 10.1038/s41375-021-01285.
    PubMed     Abstract available

  79. GOLDMAN S, Barth M, Shiramizu B, Shi Q, et al
    A dose substitution of anthracycline intensity with dose-dense rituximab in children and adolescents with good-risk mature B-cell lymphoma.
    Leukemia. 2021 May 3. pii: 10.1038/s41375-021-01256.

    April 2021
  80. CHIHARA D, Miljkovic M, Iyer SP, Vega F, et al
    Targeted based therapy in nodal T-cell lymphomas.
    Leukemia. 2021;35:956-967.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.